Evaluation the tissue inhibitor of matrix metalloproteinases first type concentration in various platelet-related products

Purpose: to evaluate the content of tissue inhibitor of matrix metalloproteinase type 1 (TIMP-1) in platelet preparations obtained in different methods.

Material and methods. Platelet-rich plasma (PRP), platelet-poor plasma, and a suspension of platelets washed from plasma (WP) were isolated from the blood of 10 volunteer donors, and a morphofunctional analysis of platelets was performed. After that, a platelet lysate was prepared from PRP, WP, and platelet-poor plasma. The concentration of TIMP-1 in the lysates was determined using enzyme immunoassay.

Results. The level of TIMP-1 in the lysates of PRP and WP did not differ significantly; in platelet-poor plasma, the level of TIMP-1 was significantly lower than in the lysates of PRP and WP (p = 0.003). In all types of preparations, the concentration of TIMP-1 was 2-4 times higher than similar values in the blood serum of healthy people, as reported in other studies. A weak correlation was found between the TIMP-1 concentration and the platelet number in PRP, and there was no correlation between the content of platelets with granules and the TIMP-1 level in the lysates. The presence of leukocytes in the initial PRP also did not affect the TIMP level in the final lysates. A strong correlation was found between the TIMP-1 concentration in the WP lysate and in platelet-poor plasma, as well as a direct correlation between the total platelet content and the TIMP-1 level in the PRP lysate.

Conclusions. Preparations with high concentrations of TIMP-1 can be obtained both from concentrated platelet suspensions and from platelet-poor plasma. To optimize the method, it is necessary to study the effect of platelet preparations with TIMP on various biological models.

1. Fedoseeva E.V., Chentsova E.V., Borovkova N.V., Alekseeva I.B., Romanova I.Yu. Peculiarities of platelet rich plasma and its application in ophthalmology. Ophthalmology in Russia. 2018; 15 (4): 388–93 (In Russ.). https://doi.org/10.18008/1816-5095-2018-4-388-393

2. Amable PR, Carias RB, Teixeira MV, et al. Platelet-rich plasma preparation for regenerative medicine: optimization and quantification of cytokines and growth factors. Stem Cell Res Ther. 2013 Jun 7; 4 (3): 67. doi: 10.1186/scrt218

3. Borovkova N.V., Makarov M.S., Andreev Yu.V., et al. Evaluation of the cytokine composition of blood serum and preparations based on human platelets. Molekulyarnaya medicina. 2021; 19 (3): 51–7 (In Russ.). doi: 10.29296/24999490-2021-03-08

4. Makarov M.S., Kobzeva E.N., Vysochin I.V., et al. Morphofunctional analysis of human platelets using vital staining Byulleten' eksperimental'noj biologii i mediciny. 2013;156 (9): 388–91 (In Russ.).

5. Delgado JJ, Sánchez E, Baro M, et al. A platelet derived growth factor delivery system for bone regeneration. J Mater Sci Mater Med. 2012 Aug; 23 (8): 1903–12. doi: 10.1007/s10856-012-4661-z

6. Filatova I.A., Pavlenko Yu.A., Shemetov S.A., et al. Efficacy of platelet-rich plasma lysate in the treatment of patients with post-traumatic eyelid scarring: an overview of clinical cases. Russian ophthalmological journal. 2021; 14 (4) (supplement): 22–6 (In Russ.). https://doi.org/10.21516/2072-0076-2021-14-4-supplement-22-26

7. Fedoseeva E.V., Chentsova E.V., Borovkova N.V., et al. A case of autologous thrombofibrin clot use in a patient with post-burn persistent corneal erosion. The Russian journal of transplantation. 2019; 11 (2): 150–7 (In Russ.). https://doi.org/10.23873/2074-0506-2019-11-2-150-157

8. Fedoseeva E.V., Chentsova E.V., Borovkova N.V., et al. Possibilities of platelet-rich plasma in the treatment of corneal defects (experimental study). Point of view. East-West. 2019; 1: 51–3 (In Russ.). doi:10.25276/2410-1257-2019-1-51-53

9. Fedoseeva E.V., Chentsova E.V., Borovkova N.V., et al. Experience of using a thrombofibrin clot of plateletrich plasma in ulcerative lesions of the cornea. Russian ophthalmological journal. 2021; 14 (4) (supplement): 15–21 (In Russ.). https://doi.org/10.21516/2072-0076-2021-14-4-supplement-15-21

10. Chentsova E.V., Borovkova N.V., Makarov P.V., et al. The biological effect of a combination of platelet lysate and amniotic membrane in buccal epithelium culture. Russian ophthalmological journal. 2022; 15 (4): 115–20 (In Russ.). https://doi.org/10.21516/2072-0076-2022-15-4-115-120

11. Loshkareva A., Majchuk D.Yu. Use of platelet-rich plasma in patients with chronic corneal erosions. Sovremennye tekhnologii v oftal'mologii. 2016; 4:131–2 (In Russ.).

12. Cooper T, Eisen A, Stricklin G, et al. Platelet-derived collagenase inhibitor: characterization and subcellular localization. Proc. of the National Academy of Sciences of the United States of America. 1985; 82 (9): 2779–83. doi:10.1073/pnas.82.9.2779

13. Murate T, Yamashita K, Isogai C, et al. The production of tissue inhibitors of metalloproteinases (TIMPs) in megakaryopoiesis: possible role of platelet- and megakaryocyte-derived TIMPs in bone marrow fibrosis. British Journal of Haematology. 1997; 99 (1): 181–9. doi:10.1046/j.1365-2141.1997.3293146.x

14. Holten-Anderson M, Brunner N, Christensen I, et al. Levels of tissue inhibitor of metalloproteinases-1 in blood transfusion components. Scandinavian Journal of Clinical and Laboratory Investigation. 2002; 62 (3): 223–30. doi:10.1080/003655102317475489

15. Zhao H, Zhao Z, Li D, et al. Efect study of exosomes derived from platelet-rich plasma in the treatment of knee cartilage defects in rats. Journal of Orthopaedic Surgery and Research. 2023; 18: 160. https://doi.org/10.1186/s13018-023-03576-0

16. Moroz Z.I., Maljugin B.Je., Gorohova M.V., Kovshun E.V. UV cross-linked donor corneas for penetrating keratoplasties in corneal perforations. Ophthalmosurgery. 2014; 2: 29–32 (In Russ.).

17. Chentsova E.V., Verigo E.N., Makarov P.V., et al. Crosslinking in the complex treatment of corneal ulceration and corneal grafting. Russian ophthalmological journal. 2017; 10 (3): 93–100 (In Russ.). https://doi.org/10.21516/2072-0076-2017-10-3-93-100

18. Orchard J, Massey A, Brown R, Cardon-Dunbar A, Hofmann J. Successful management of tendinopathy with injections of the MMP-inhibitor aprotinin. Clinical Orthopaedics and Related Research. 2008; 466 (7): 1625–32. https://doi.org/10.1007/s11999-008-0254-z

19. Sen Е, Balikoglu-Yilmaz M, Bozag-Pehlivan S, et al. Effect of doxycycline on postoperative scarring after trabeculectomy in an experimental rabbit model. Journal of ocular pharmacology and therapeutics: history and future directions. 2010; 26 (5): 399–406. https://doi.org/10.1089/jop.2010.0064

20. Li D, Zhou N, Zhang L, et al. Pflugfelder Suppressive Effects of Azithromycin on Zymosan-Induced Production of Proinflammatory Mediators by Human Corneal Epithelial Cells. Invest Ophthalmol Vis Sci. 2010; 51 (11): 5623–9. https://doi.org/10.1167/iovs.09-4992

21. Lee E, Vaughan D, Parikh S, et al. Regulation of matrix metalloproteinases and plasminogen activator inhibitor-1 synthesis by plasminogen in cultured human vascular smooth muscle cells. Circulation Research. 1996; 78 (1): 44–9. https://doi.org/10.1161/01.res.78.1.44

22. Shu-Chen C, Shun-Fa Y, Ko-Huang L. Regulation of gelatinases expression by cytokines, endotoxin, and pharmacological agents in the human osteoarthritic knee. Connective Tissue Research. 2004; 45 (3): 142–50. https://doi.org/10.1080/03008200490506058

23. Villeneuve J, Block A, Le B, et al. Tissue inhibitors of matrix metalloproteinases in platelets andmegakaryocytes: a novel organization for these secreted proteins. Experimental Hematology. 2009; 37 (7): 849–56. https://doi.org/10.1016/j.exphem.2009.03.009